朗姿股份(002612) - 朗姿股份投资者关系管理信息

Financial Performance - In the first three quarters of 2024, the company achieved total revenue of approximately 4.178 billion CNY, a year-on-year increase of 1.45% [1] - Gross profit margin was 58.92%, up by 1.64 percentage points compared to the same period last year [1] - Net profit attributable to shareholders was approximately 209 million CNY, a decrease of 4.87% year-on-year, primarily due to significant non-recurring gains in the previous year [1] - After deducting non-recurring items, net profit attributable to shareholders was approximately 180 million CNY, an increase of 11.29% year-on-year [1] Cash Flow and Earnings - Net cash flow from operating activities for the first three quarters of 2024 was approximately 356 million CNY, a decrease of 45.51% [1] - Basic earnings per share were 0.4729 CNY, down by 4.87% year-on-year [1] - The weighted average return on net assets was 5.96% [1] Asset Overview - As of September 30, 2024, total assets were approximately 8.271 billion CNY, a decrease of 1.11% from the end of the previous year [2] - Net assets attributable to shareholders were approximately 3.116 billion CNY, down by 12.35% from the end of the previous year [2] Business Segment Performance - The medical beauty segment generated approximately 2.071 billion CNY in revenue, accounting for 49.9% of total revenue, with a year-on-year growth of 2.73% [2] - The women's clothing segment achieved approximately 1.406 billion CNY in revenue, representing 33.7% of total revenue, with a year-on-year increase of 2.15% [2] - The infant and toddler segment reported approximately 685 million CNY in revenue, accounting for 16.4% of total revenue, a decrease of 4.9% year-on-year [2] Inventory and Supply Chain - As of September 30, 2024, total inventory for women's clothing was 755 million CNY, an increase of 8.04% from the end of the previous year [3] - The inventory structure improved, with a significant increase in inventory for products within one year, up by 34.85% compared to the beginning of the year [3] Strategic Direction - The medical beauty segment is becoming the largest business area in terms of revenue and profit, with plans to accelerate national expansion and become an industry leader [3] - The company aims to enhance collaboration with upstream suppliers to improve product offerings and R&D capabilities [3]